{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:50Z","timestamp":1790774450733,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"AnGes"},{"DOI":"10.13039\/100011338","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013711","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CESCA"},{"DOI":"10.13039\/100002232","name":"Mitsubishi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002232","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pluristem"},{"name":"N Weiss"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006031","name":"Bard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006031","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003389","name":"Fresenius","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pluristem"},{"DOI":"10.13039\/100006432","name":"Terumo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006432","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pluristem"},{"name":"Pluristem"},{"DOI":"10.13039\/100013711","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003898","name":"Jansen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003898","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pluristem"},{"DOI":"10.13039\/100013711","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003898","name":"Jansen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011338","name":"AstraZenca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MedUpdate"},{"name":"NephroUpdate"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pluristem"},{"DOI":"10.13039\/501100007601","name":"European Union's Horizon 2020 Research and Innovation Programme","doi-asserted-by":"publisher","award":["733006"],"award-info":[{"award-number":["733006"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejves.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Vascular and Endovascular Surgery"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejvs.2018.11.008","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T02:22:52Z","timestamp":1548555772000},"page":"538-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial"],"prefix":"10.1016","volume":"57","author":[{"given":"Lars","family":"Norgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Nikol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hinchliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racheli","family":"Ofir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zami","family":"Aberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejvs.2018.11.008_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2018.11.008_bib3","first-page":"e726","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology\/American Heart association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2018.11.008_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejvs.2017.07.018","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Aboyans","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Effect of fibroblast growth factor NV1FGF on amputation and death: a randomized placebo-controlled trial of gene therapy in critical limb ischemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2018.11.008_bib6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critrical limb ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejvs.2018.11.008_bib7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","article-title":"Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia","volume":"17","author":"Shigematsu","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.ejvs.2018.11.008_bib8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jvs.2010.07.044","article-title":"Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lowere extremity ulceration: results of the HGF-0205 trial","volume":"52","author":"Powell","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib9","first-page":"5","article-title":"Gene-therapeutic strategies targeting angiogenesis in peripheral artery disease","volume":"30","author":"Sanada","year":"2018","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.ejvs.2018.11.008_bib10","first-page":"503","article-title":"Therapeutic angiogenesis for peripheral artery disease","volume":"2","author":"Iver","year":"2017","journal-title":"JACC Basic Trans Sci"},{"key":"10.1016\/j.ejvs.2018.11.008_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(02)09670-8","article-title":"Theraputic angiogenesis for patients with critical limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial","volume":"360","author":"Tateishi-Yuyama","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2018.11.008_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.114.012913","volume":"131","author":"Teraa","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2018.11.008_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/SLA.0b013e3182854cf1","article-title":"Autologous bone marrow derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials","volume":"258","author":"Teraa","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ejvs.2015.08.018","article-title":"Bone marrow derived cell therapy in critical limb ischemia: a meta-analysis of randomized placebo controlled trials","volume":"50","author":"Peeters Weem","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1358863X17752556","article-title":"Therapeutic efficacy of CD34+ cell-involved mononuclear cell therapy for no-option critical limb ischemia: a meta-analysis of randomized controlled clinical trials","volume":"23","author":"Pan","year":"2018","journal-title":"Vasc Med"},{"key":"10.1016\/j.ejvs.2018.11.008_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa022287","article-title":"Circulating endothelial progenitor cells, vascular function and cardiovascular risk","volume":"348","author":"Hill","year":"2003","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ejvs.2018.11.008_bib17","doi-asserted-by":"crossref","first-page":"e55592","DOI":"10.1371\/journal.pone.0055592","article-title":"Bone marrow alteration and lower endothelial progenitor cell numbers in critical limb ischemia patients","volume":"8","author":"Teraa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejvs.2018.11.008_bib18","first-page":"77","article-title":"Adverse events during treatment of critical limb ischemia with autologous peripheral blood mononuclear cell implant","volume":"31","author":"Jonsson","year":"2012","journal-title":"Int Angiol"},{"key":"10.1016\/j.ejvs.2018.11.008_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-015-0240-9","article-title":"The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy","volume":"6","author":"Zhang","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ejvs.2018.11.008_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jss.2013.05.084","article-title":"Cardioprotection by placenta-derived stromal cells in a murine myocardial infarction model","volume":"185","author":"Roy","year":"2013","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.ejvs.2018.11.008_bib21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcyt.2017.09.010","article-title":"Placenta-derived PLX-PAD mesenchymal-like stromal cells are efficacious in rescuing blood flow in hind limb ischemia mouse model by a dose- and site-dependent mechanism of action","volume":"19","author":"Zahavi-Goldstein","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejvs.2018.11.008_bib22","first-page":"619","article-title":"Mechanisms of action of angiogenin","volume":"40","author":"Gao","year":"2008","journal-title":"Acta Biochim Biophys Sin(shanghai)"},{"key":"10.1016\/j.ejvs.2018.11.008_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14653240902849762","article-title":"The role of placenta derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia","volume":"11","author":"Prather","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejvs.2018.11.008_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejvs.2011.04.030","article-title":"Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia","volume":"42","author":"Van Belle","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/ehv006","article-title":"Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence","volume":"36","author":"Reinecke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejvs.2018.11.008_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.avsg.2010.08.006","article-title":"Emerging national trends in the management and outcomes of lower extremity peripheral arterial disease","volume":"25","author":"Hong","year":"2011","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ejvs.2018.11.008_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.23736\/S0392-9590.18.03986-X","article-title":"Predicitve factors of a poor outcome following revascularization for critical limb ischemia: implications for practice","volume":"37","author":"Martinez","year":"2018","journal-title":"Int Angiol"},{"key":"10.1016\/j.ejvs.2018.11.008_bib28","doi-asserted-by":"crossref","first-page":"e115963","DOI":"10.1371\/journal.pone.0115963","article-title":"Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem\/stromal cells","volume":"9","author":"Beane","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejvs.2018.11.008_bib29","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/stem.2104","article-title":"Mesenchymal stromal cells prevent allostimulation in\u00a0vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation","volume":"33","author":"Consentius","year":"2015","journal-title":"Stem Cells"}],"container-title":["European Journal of Vascular and Endovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078588418308566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078588418308566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:51:00Z","timestamp":1761047460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078588418308566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1078588418308566"],"URL":"https:\/\/doi.org\/10.1016\/j.ejvs.2018.11.008","relation":{},"ISSN":["1078-5884"],"issn-type":[{"value":"1078-5884","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Vascular and Endovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejvs.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society for Vascular Surgery. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}